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Corpora with speciﬁc entities and relationships annotated are essential to train and evaluate text-mining
systems that are developed to extract speciﬁc structured information from a large corpus. In this paper
we describe an approach where a named-entity recognition system produces a ﬁrst annotation and anno-
tators revise this annotation using a web-based interface. The agreement ﬁgures achieved show that the
inter-annotator agreement is much better than the agreement with the system provided annotations. The
corpus has been annotated for drugs, disorders, genes and their inter-relationships. For each of the drug–
disorder, drug–target, and target–disorder relations three experts have annotated a set of 100 abstracts.
These annotated relationships will be used to train and evaluate text-mining software to capture these
relationships in texts.
 2012 Elsevier Inc. All rights reserved.1. Introduction
Systems for automated extraction of information from large
corpora of biomedical documents hold promise as an adjunct to
human information processing capabilities. For example, informa-
tion extraction systems have applications in the support of data-
base curation [1], interpretation of high-throughput experiments
[2], and discovery of novel protein–protein interactions [3].
To develop and evaluate such systems annotated corpora are
necessary. Most currently available corpora have annotations for
only one type of entity, and only very few annotate relationships
between entities. The entities most frequently annotated are
proteins and genes, with relationship annotation focusing on
protein–protein interactions. However, relationships involving
other entities, such as drugs and diseases, are increasingly being
studied. In the EU-ADR project, for example, data mining of mas-
sive amounts of electronic health records generates many potential
signals (drug–disease combinations in which the disease can be
considered as an adverse event due to the drug) [4]. If a drug–
disease association is reported in literature, the signal can be dis-
carded; else drug–target (proteins, genes, and gene variants) and
target–disease relationships are sought to substantiate the signal,ll rights reserved.
. van Mulligen).i.e., to ﬁnd a plausible biological mechanism that can explain the
signal. Systems to automatically retrieve these relationships from
scientiﬁc literature and databases would be very helpful, but anno-
tated corpora to train and test these systems are currently not
available.
Another limitation of most existing corpora is that they do not
provide information about the agreement between the corpus
annotators. This makes it difﬁcult to compare the performance of
an automated system with that of an individual human annotator.
In this study we describe the construction of a corpus, dubbed
the EU-ADR corpus, which contains annotations of multiple enti-
ties (drugs, diseases, and targets) and relationships between these
entities. Inter-annotator agreement scores are also provided.2. Background
Annotated corpora have been developed for a number of bio-
medical domains, mostly focusing on gene and protein annota-
tions. The Genia corpus v3.0 consists of 2000 Medline abstracts
that have been annotated for a subset of the substances and the
biological locations involved in reactions of proteins [5,6]. Several
corpora were constructed as part of the BioCreative challenges
[7]. One corpus consisted of 20,000 sentences from Medline
abstracts, which were annotated for genes and proteins [8]. In
another corpus, consisting of 358 full-text documents curated by
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at the abstract level, i.e., the annotators did not indicate the
location of the interacting proteins in the text. Another example
of an annotated corpus is PennBioIE [9]. It provides annotations
of proteins and malignancies (cancer) for 2258 PubMed abstracts.
In many of these corpora apart from the medical entities also
lexical information (paragraphs, sentences, and part of speech)
are provided.
Few corpora have been annotated for drugs and diseases. A sub-
set of 1731 texts has been extracted from the PharmGKB database
and annotated for drugs, diseases, and genes, together with their
relationships [10,11]. The annotations only indicate terms and
relationships that are mentioned in an abstract, not their actual
location in the text. The corpus is not publicly available.
In the BioText corpus [12] several relationships between disor-
ders and treatments have been annotated. It is composed of 100
titles and 40 abstracts from Medline. The treatments comprise
both drugs and medical treatments. The annotations are performed
at the sentence level. Both positive and negative relationships have
been annotated.
For testing chemical dictionaries a manually annotated set of
100 PubMed abstracts has been used for the SCAI corpus [13]. Based
on a complexity indicator for chemical terms a set of abstracts has
been selected and annotated by two independent annotators.
Leaman developed a manually annotated disease and symp-
toms corpus – known as the Arizona Disease Corpus – existing of
794 PubMed abstracts [14]. This set does however not contain
adverse effects mentions. The corpus contains the location of the
mentions of a disease or symptom and the mapping to an equiva-
lent UMLS concept. This corpus is freely downloadable.
Some corpora provide annotations that were generated by auto-
matic means. EDGAR is a corpus of 103 PubMed abstracts about
cancer, which has been annotated for drugs, genes and the rela-
tionships between these entities by the EDGAR program [15]. The
Wisconsin corpus [16] is composed of 1,529,731 sentences that
were annotated automatically for three types of relationships:
gene–disorder, protein–protein interaction and protein–subcellu-
lar localization. The locations of the entities are not provided and
human experts did not review the annotations in these corpora
for their quality.
Almost all these corpora are used either for training and evalu-
ating text mining systems and typically one ﬁnds precision, recall
and f-measures describing the quality of the system under evalua-
tion against the gold standard. However, only little data is provided
by the constructors of these corpora on the inter-annotator agree-
ment (IAA). Sometimes, a description of the annotation guidelines
is given with a process to reﬁne the annotations into a certain
consensus. Roberts presented in his paper on the CLEF corpus
how inter-annotator agreement was computed (with a relaxed
and corrected IAA) [17].
Summarizing, existing corpora often focus on the annotation of
single entities, provide only limited relationship annotation, if any,
and do not provide inter-annotator agreement scores. A corpus
with annotations for drug–disease, drug–target, and target–disease
relationships is not available. Here we report on the construction of
such a corpus.
3. Material and methods
3.1. Strategy for corpus development
The development of the EU-ADR corpus consisted of the follow-
ing phases:
 Deﬁnition of the scope of the corpus and ﬁrst version of the
annotation guidelines. Selection of the expert annotators within the EU-ADR project.
Five experts volunteered to participate in the annotation pro-
ject. Their area of expertise covers molecular biology, phar-
macology, pharmacogenomics, and pharmacovigilance.
Based on the individual expertise of each annotator, each of
them was assigned to different annotation tasks.
 Pilot annotation experiment. A pilot annotation exercise was
conducted on a small set of documents in order to train the
annotators, learn how to use the annotation tool, reﬁne the
annotation guidelines, and evaluate the time and effort
required for annotation.
 Document selection from Medline.
 Start of annotation project.
 Evaluation of the annotations. Analysis of the inter-annotator
agreement, development of the ﬁnal, consensus EU-ADR
corpus.
The annotation was performed on Medline abstracts. Text from
the title and the abstract was annotated at the sentence level. An
important consideration in development of a corpus is the way
the annotations are encoded in the text. It is not enough to say that
an article describes an association between drug X and target Y,
but pointers to the text fragments that denote the drug X and
the target Y have to be provided.
3.2. Annotation guidelines
The annotation guidelines were developed after manual inspec-
tion of abstracts concerning the relationships of interest to the pro-
ject and our previous survey on biomedical corpora. In addition,
the GENIA project for annotation of biomedical events [18] and
the BioIE project [20] were used as guides for the preparation of
the guidelines. Here we only provide the general guidelines used
in the annotation of the EU-ADR corpus:
1. Associate all the annotations with actual expressions in the
text. This is known as ‘‘Text-bound annotations’’, as described
in [18].
2. The annotations were performed on single sentences. All the
evidence for a relationship should come from the same sen-
tence. The context (the rest of the abstract) can be used for
disambiguation.
3. Annotate only relationships between the entities drug, target,
and disease. Other types of relationships should not be
annotated.
4. Annotate relationships according to the provided categories.
Relationships that do not belong to these categories should
not be annotated.
5. Entities will be already annotated in the text by means of an
automatic NER system (Peregrine) [19]. Annotators will have
to check if the annotation of entities is correct, and perform
additional annotation of entities if they ﬁnd an entity that
was missed by the NER system.
3.3. Entity annotation
This task involves the identiﬁcation of text spans that corre-
spond to the biomedical entities of our interest: drug, targets,
and diseases. The annotation tool provided the pre-annotation of
entities. Thus, the annotators did not have to annotate entities
from scratch, unless the NER system Peregrine [21] missed entities
or annotated them incorrectly. Peregrine uses a thesaurus that con-
tains per concept all term variations, its deﬁnition, external identi-
ﬁers/codes, and the semantic type and hierarchical relations. It will
use the terms to detect in the text occurrences of the concept
(maximum term matching) and attach the concept identiﬁer to
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of entities is correct, and perform additional annotation of entities
if they found an entity that was missed or incorrectly annotated by
Peregrine.
The entities on which we focus have been deﬁned as follows:
 Target: genes, proteins and sequence variants of genes and
proteins. More speciﬁcally:
– Gene/RNA: a gene or RNA element, and families of genes.
– Protein: gene products, protein complexes and protein
families.
– Variation: any type of sequence variation within the pop-
ulation as well as mutations.
This corresponds to the types Genes & Molecular sequences and
SNP & Sequence variants in the annotation tool.
 Disease: disease phenotypes of the adverse drug reactions. In
EU-ADR we focus on ADRs, most of which will classify as dis-
orders according to the UMLS Metathesaurus. Thus, disease
phenotypes in general are annotated, which correspond to
the type ‘‘Diseases & Disorders’’ in the annotation tool.
 Drug: biologically active chemicals, marketed drugs and drug
metabolites. Drug classes are also allowed. This corresponds
to the type ‘‘Chemicals & Drugs’’ in the annotation tool.
3.4. Relationship annotation
In this annotation project we considered only three relation-
ships between entities. In addition, for each relationship, we spec-
iﬁed the type of the relationship according to the level of certainty.
The relationships considered are the following:
 Target–disease: this relationship indicates if the target is asso-
ciated with the disease, for instance, if the target plays a role
in the mechanism underlying the disease, or is a marker of
the disease, or if there is any evidence that is associated to
the disease.
 Target–drug: this relationship indicates if the drug binds to a
protein target, but also if the drug affects gene expression or
modiﬁes in some way the gene or the protein function.
 Drug–disease: this relation indicates if the drug is associated
with the disease, for instance, if the drug may produce an
adverse effect.
Once we have identiﬁed a relationship between two entities, we
have to specify the type of the relationship. The relationship types
are deﬁned with respect to the level of certainty used to express a
relationship in the text at the sentence level:
 Positive association (PA): the sentence clearly states that there
is an association between the entities.
 Negative association (NA): the sentence clearly states that
there is no association between the entities.
 Speculative association (SA): the sentence describes a putative
relationship between the target and the disease. This might
be conﬁrmed or refuted later in the abstract, but in the sen-
tence under study the relationship is presented as a
speculation.
We illustrate these types using the target–disease relationship
in which the targets are SNPs.
 Positive association: the sentence states that the SNP is associ-
ated with the disease. It can be a causative association (the
SNP introduces a change that causes the disease), a markerassociation (the SNP is in linkage disequilibrium with the
‘‘real’’ causative variation, which is not known, thus the SNP
can be used as a disease marker).
Examples (entities shown in bold):
‘‘We report on 3 sisters with severe hyperhomocysteinemia
due to homozygosity for the CBS 833T ? C mutation’’.
‘‘A point mutation was observed in an individual diagnosed
with HEP, resulting in an alanine to glycine change at
amino acid position 80 and was present on both alleles’’.
‘‘Our data provide the ﬁrst evidence that the Cdc6 G1321A
polymorphism is associated with decreased risk of cancer’’.
 Negative association: the sentence states that there is no asso-
ciation between the SNP and the disease phenotype. With this
category we consider negative ﬁndings in the literature
regarding relationships.
Example:
‘‘The frequency of Lys-251 was 10-fold greater in African-
Americans than in Caucasians, but was not associated with
essential hypertension’’.
 Speculative association: the association is expressed as a
hypothesis, can be identiﬁed by the use of expressions such
as ‘‘might be’’, ‘‘suggest’’, etc.
Example:
‘‘The Met98Lys change may be associated with a fraction of
normal-tension glaucoma in patients of Japanese ethnicity’’.
In summary, the relationship types apply to each relationship
(target–disease, target–drug, drug–disease), and indicate the level
of certainty used to express a fact in text.
3.5. Document selection
Three sets of 100 Medline abstracts were obtained (from 2007
until 2008) using PubMed with four different queries (Table 1).
For the drug–disorder and drug–target relation 100 abstracts were
randomly selected from the PubMed result. The target–disorder set
was composed of 50 randomly selected abstracts for gene-disorder
and 50 from the SNP–disorder relation. Only for the drug–disorder
query the ‘‘adverse effects’’ subheading is applicable and added.
There were no other similar subheadings available for the other
relations. Three experts independently annotated the entities and
their inter-relations for each abstract in each of the three sets of
100 abstracts according to the annotation guidelines described be-
low. Some experts annotated more than one set.
3.6. Annotation tool
A web-based annotation tool has been developed that assisted
the experts in the annotation tasks (see Fig. 1). The main features
of the annotation tool are: it is a web-based system and the
annotations are stored server-side per annotator; entities
are pre-annotated automatically, the annotator has to correct these
annotations and provide new ones if required; relation annotations
are automatically generated based on co occurrence of entities in
one sentence; the system provides standoff annotations. The tool
is based on software from Knewco [21] that shows in-text high-
lights of terms recognized by the named entity recognition (NER)
system Peregrine. The relations between the terms are automati-
cally derived based on co occurrence and limited to the semantic
types of the selected annotation relationship – so for the drug–dis-
order relationship only co occurrences between a drug and a disor-
der are considered – and proposed to the annotator. The annotator
can revise the entities marked up and the relations found indicat-
ing the presence of the relationship and its type. In addition, the
annotators can add new entities if required.
In order to minimize the burden on the annotators we
integrated a NER system – Peregrine – to pre-annotate a PubMed
Table 1
PubMed queries used to construct the different annotation sets.
Relation Query
Drug–disorder (‘‘Inorganic Chemicals’’[Mesh] OR ‘‘Organic
Chemicals’’[Mesh] OR ‘‘Heterocyclic Compounds’’[Mesh] OR
‘‘Polycyclic Compounds’’[Mesh] OR
‘‘Hormones,
Hormone Substitutes, and Hormone Antagonists’’[Mesh] OR
‘‘Carbohydrates’’[Mesh] OR ‘‘Lipids’’[Mesh] OR ‘‘Amino
Acids, Peptides, and
Proteins’’[Mesh]
OR ‘‘Nucleic Acids, Nucleotides, and Nucleosides’’[Mesh] OR
‘‘Biological Factors’’[Mesh] OR ‘‘Biomedical and Dental
Materials’’[Mesh] OR
‘‘Pharmacologic
Actions’’[Mesh]) AND ‘‘Diseases Category’’[Mesh] AND
hasabstract[text] AND (‘‘2007’’[PDAT]: ‘‘2008’’[PDAT]) AND
‘‘humans’’[MeSH Terms] AND
English[lang] AND ‘‘adverse effects’’[Subheading]
Drug–target (‘‘Inorganic Chemicals’’[Mesh] OR ‘‘Organic
Chemicals’’[Mesh] OR ‘‘Heterocyclic Compounds’’[Mesh] OR
‘‘Polycyclic Compounds’’[Mesh] OR
‘‘Hormones,
Hormone Substitutes, and Hormone Antagonists’’[Mesh] OR
‘‘Carbohydrates’’[Mesh] OR ‘‘Lipids’’[Mesh] OR ‘‘Amino
Acids, Peptides, and
Proteins’’[Mesh]
OR ‘‘Nucleic Acids, Nucleotides, and Nucleosides’’[Mesh] OR
‘‘Biological Factors’’[Mesh] OR ‘‘Biomedical and Dental
Materials’’[Mesh] OR
‘‘Pharmacologic
Actions’’[Mesh]) AND ‘‘Proteins’’[Mesh] AND
hasabstract[text] AND (‘‘2007’’[PDAT]: ‘‘2008’’[PDAT]) AND
‘‘humans’’[MeSH Terms] AND English[lang]
AND (‘‘agonists’’[Subheading] OR ‘‘antagonists and
inhibitors’’[Subheading] OR ‘‘Gene Expression Regulation/
drug effects’’[Mesh])
Gene–disorder (‘‘Diseases Category’’[Mesh] AND ‘‘genetics’’[Subheading]
AND (hasabstract[text] AND (‘‘2007’’[PDAT]: ‘‘2008’’[PDAT])
AND ‘‘humans’’[MeSH Terms]
AND English[lang]))
SNP–disorder (‘‘Polymorphism, Single Nucleotide’’[Mesh] AND
(hasabstract[text] AND (‘‘2007’’[PDAT]: ‘‘2008’’[PDAT]) AND
‘‘humans’’[MeSH Terms] AND
English[lang]) AND ‘‘Diseases Category’’[Mesh])
Fig. 1. An interactive web-based application allows the annotator to add new annotatio
items indicate the entities that have been annotated, with each color representing a diffe
‘save’ is selected and can be pulled up anytime. The relationships can be annotated as
example. (For interpretation of the references to color in this ﬁgure legend, the reader i
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opens the abstract for the ﬁrst time the entities as identiﬁed by the
NER system are already marked in the text. The annotator can
modify or delete system annotations very easily. After the annota-
tion is saved the system annotation is not available anymore. The
web interface automatically computes per sentence a set of rela-
tions that according to the relation type can be derived. Again,
the annotator can modify or delete these suggested relations. As
soon as the user marks a new entity, the set of relations is updated.3.7. Inter-annotation agreement
Since the annotations are performed based on background
knowledge and also on the particular context of the text, measures
to control for the variability of the annotations have to be consid-
ered. Clear and detailed annotation guidelines and the use of ‘‘text
bound’’ annotation can reduce, but not eliminate, the variability
between annotators. A measure of the inter-annotator agreement
was used to estimate how the annotations differed between anno-
tators and to look for strategies to get a consensus annotation. In
order to maximize the agreement on the annotation of relation-
ships, which is the main goal of the project, we allowed some ﬂex-
ibility on the annotation of entities (for instance by allowing
variable boundaries on the annotation of entities).
To harmonize the different annotations, a simple majority-
voting scheme was applied: if two of the three annotators agreed
on a given annotation, it became part of the ﬁnal EU-ADR corpus.
If only one annotator gave an annotation, it was discarded. To al-
low for slightly differing entities marked by different annotators,
we applied a matching scheme that regarded terms as a match if
they shared at least one word rather than a scheme that requires
terms to match exactly. For example, one annotator may have
marked ‘‘diabetes’’ whereas the other marked ‘‘severe diabetes’’.
With exact match, this would be considered a disagreement,
whereas one may argue that the annotators agreed on the term
‘‘diabetes’’. A relationship was only included in the corpus if there
was agreement both on the entities involved and on the type of the
relationship (positive, negative, and speculative). Preliminary
analysis of the inter-annotator agreement on the relationshipsns or modify annotations suggested by the NER system in an easy way. The colored
rent type of entity. The annotations are saved at the server side per annotator when
well with different association types. Note: the data here shown only serves as an
s referred to the web version of this article.)
Table 3
Agreement between the annotators (A1–A5) and the automatic tool against the EU-
ADR corpus for the annotated entities.
Relationship type A1 A2 A3 A4 A5 NER system
Drug–disorder 0.83 0.78 0.87 0.73
Target–disorder 0.80 0.84 0.88 0.63
Target–drug 0.82 0.83 0.87 0.67
Overall 0.82 0.83 0.88 0.78 0.87 0.67
Table 4
Agreement between the annotators (A1–A5) and the automatic tool against the EU-
ADR corpus for the annotated relationships.
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speculative associations among the annotators. Thus, speculative
and positive relationships were considered equivalent when
assessing inter-annotator agreement. If relations were typiﬁed as
speculative they were always annotated by other annotators as
either speculative or positive. We assumed therefore that negative
speculative relations are unlikely to occur in our corpus. Therefore
we treated the speculative and positive relations as similar for
computing agreement. As an example, the relation between the
drug ‘‘RTX’’ and the disorder ‘‘pSS’’ in the following sentence ‘‘Con-
trolled trials should be performed to conﬁrm the efﬁcacy of RTX in
pSS. [PubMed, PMID: 16950808]’’ was annotated both as specula-
tive and as positive.Relationship type A1 A2 A3 A4 A5 NER system
Drug–disorder 0.75 0.51 0.83 0.69
Target–disorder 0.85 0.72 0.71 0.57
Target–drug 0.77 0.79 0.50 0.79
Overall 0.80 0.75 0.62 0.51 0.83 0.66
Table 5
Per relationship type the inter-annotator (and NER system) agreement statistics.
A1 A4 A5 NER system
Drug–disorder
A1 1.00 0.78 0.72 0.59
A4 0.78 1.00 0.70 0.64
A5 0.72 0.70 1.00 0.56
NER system 0.59 0.64 0.64 1.00
Target–disorder
A1 1.00 0.73 0.74 0.46
A2 0.73 1.00 0.75 0.49
A3 0.74 0.75 1.00 0.58
NER system 0.46 0.49 0.58 1.00
Target–drug
A1 1.00 0.78 0.75 0.49
A2 0.78 1.00 0.74 0.52
A3 0.75 0.74 1.00 0.58
NER system 0.49 0.52 0.58 1.004. Results
Based on all annotations of entities and relationships we can
analyze the number of entities and relations for whom a majority
exists and in consequencewere included in the ﬁnal EU-ADR corpus
(see Table 2). Although the agreement on the relationships is low
we have to take into account that a relation can only be included
if both entities for which the relationship holds are agreed upon.
The second percentage under the relationships agreement shows
the agreement given that the annotators agreed on the two entities.
Given that correction, it is evident that the clarity and complexity of
how a relation is expressed depends on the type of entities involved
in the relation and as a consequence impacts the agreement. Agree-
ment has been computed as the fraction of all annotations onwhich
the annotator is in agreement with the majority.
In order to test the agreement of each annotator with the
EU-ADR corpus we computed both the agreement statistics for
both the entities (Table 3) and the relations (Table 4). The agree-
ment ﬁgures show a good correspondence between the different
annotations. From the results we can see that apart from annotator
A4 all annotators show a good agreement with the EU-ADR corpus.
In addition to comparing the annotations against the annotated
corpus we also computed the inter-annotator agreement for each
relationship (Table 5).5. Discussion
The agreement statistics are comparable with what has been
shown in other annotation efforts [13,17]. The agreement on the
entity annotation is a little higher than on the relationships. One
reason for this is that it may be difﬁcult for annotators to distin-
guish between a relationship being described in the text and the
relationship actually being true. During the training that preceded
the annotation effort it was clear that some annotators had
difﬁculty to distinguish these differences, however further
clariﬁcations were made to the guidelines following consensualTable 2
Number of annotated entities and relationships and their agreement in the EU-ADR corpu
agreement on the entities.
Relationship type Entities Total Ag
Drug–disorder Drugs 929 73
Disorders 1029 81
Total 1958 15
Target–disorder Targets 1664 11
Disorders 964 72
Total 2628 19
Target–drug Target 1601 12
Drugs 824 58
Total 2425 18
Overall 7011 52discussions. It can also be related to the lack of information pro-
vided in the abstract to assess the relationships.
Even though a named entity recognition system has been used
to suggest annotations to the annotators the agreement between
this system and the annotators is lower than the inter-annotator
agreement. The inter-agreement is the fraction of all annotations
where two annotators agree. This means that the annotators mod-
iﬁed the suggested annotations and were consistent on suggestions
for change. Nevertheless, in our experience the use of NER system
is highly recommended to facilitate the annotation.
The web-based interface made it possible for the annotators to
easily make annotations without the need to install any software.s. For the relationships agreement the second percentage shows the agreement given
reement entities Relations Agreement relations
9 (79.5%) 668 300 (44.9%, 71.5%)
2 (78.9%)
51 (79.2%)
77 (70.7%) 941 424 (45.1%, 86.3%)
4 (75.1%)
01 (72.3%)
41 (77.5%) 827 313 (37.8%, 66.7%)
7 (71.2%)
28 (75.3%)
80 (75.3%) 2436 1037 (42.5%, 74.7%)
884 E.M. van Mulligen et al. / Journal of Biomedical Informatics 45 (2012) 879–884The web-based interface kept track of the progress and stored the
annotations at a secure central server based at the Erasmus Univer-
sity Medical Center.6. Conclusion
We have developed a corpus of 300 abstracts with drugs, disor-
ders and targets and their inter-relationships annotated. The anno-
tators achieved a consistently high agreement and improved on the
computer annotation that was provided as a ﬁrst annotation. We
foresee that the availability of such a corpus will be useful for
the development and testing of text-mining tools.
For evaluating and training text-mining systems on an anno-
tated corpus it is essential to know the agreement on the annota-
tions. It is therefore essential to provide with each annotated
corpus data on the inter-annotator agreement.7. Availability
The EU-ADR corpus can be downloaded from: http://euadr.eras-
musmc.nl/sda/euadr_corpus.tgz
The annotation tool is available online at the following URL:
http://euadr.erasmusmc.nl/sda/annotate.py
Acknowledgments
This research received funding from the European Union
Community in the framework of the FP7/2007–2013 convention-
governing subsidy no. 215847 – the EU-ADR project, the Innovative
Medicines Initiative [eTOX,115002], and the Instituto de Salud
Carlos III FEDER (CP10/00524). The Research Programme on
Biomedical Informatics (GRIB) is a node of the Spanish National
Institute of Bioinformatics (INB) and a member of the COMBIOMED
network.
References
[1] Yeh AS, Hirschman L, Morgan AA. Evaluation of text data mining for database
curation: lessons learned from the KDD Challenge Cup. Bioinformatics
2003;19(1):331–9.
[2] Loging W, Lee Harland L, Williams-Jones B. High-throughput electronic
biology: mining information for drug discovery. Nat Rev Drug Discov
2007;6:220–30.[3] van Haagen HHHBM, ‘t Hoen PAC, Botelho Bovo A, de Morrée A, van Mulligen
EM, et al. Novel protein–protein interactions inferred from literature context.
PLoS One 2009;4(11):e7894.
[4] Coloma PM, Schuemie MJ, Triﬁrò G, Gini R, Herings R, Hippisley-Cox J, et al.
Combining electronic healthcare databases in Europe to allow for large-scale
drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf
2011;20(1):1–11.
[5] Tateisi Y, Yuka, Yakushiji A, Ohta R, Tsujii J. Syntax annotation for the GENIA
corpus. In: Proceedings of the IJCNLP 2005, Companion volume. Jeju Island,
Korea; October, 2005. p. 222–7.
[6] Kim J-D, Ohta T, Tateisi Y, Tsujii J. GENIA corpus—a semantically annotated
corpus for bio-textmining. Bioinformatics 2003;19(1):180–2.
[7] Hirschman L, Yeh A, Blaschke C, Valencia A. Overview of BioCreAtIvE: critical
assessment of information extraction for biology. BMC Bioinformatics
2005;6(1).
[8] Smith L et al. Overview of BioCreative II gene mention recognition. Genome
Biol 2008;9:S2.
[9] Mandel MA. Integrated annotation of biomedical text: creating the PennBioIE
corpus. In: Proceedings of the workshop on text mining, ontologies and natural
language processing in biomedicine, 20–21 March, 2006, Manchester, UK;
2006.
[10] Garten Y, Coulet A, Altman RB. Recent progress in automatically extracting
information from the pharmacogenomic literature. Pharmacogenomics
2010;11(10):1467–89.
[11] Garten Y, Tatonetti NP, Altman RB. Improving the prediction of
pharmacogenes using text-derived drug–gene relationships. Pac Symp
Biocomput 2010;15:305–14.
[12] Rosario B, Hearst MA. Classifying semantic relations in bioscience text. In:
Proceedings of the 42nd annual meeting of the association for computational
linguistics (ACL 2004), Barcelona; July, 2004.
[13] Kolárˇik C, Klinger R, Friedrich CM, Hofmann-Apitius M, Fluck J. Chemical
names: terminological resources and corpora annotation. In: Proceedings of
the LREC 2008 workshop on building and evaluating resources for biomedical
text mining; 2008.
[14] Leaman R, Miller C, Gonzalez G. Enabling recognition of diseases in biomedical
text with machine learning: corpus and benchmark. In: Handbook of the 3rd
international symposium on languages in biology and medicine; 2009.
[15] Rindﬂesch TC, Tanabe L, Weinstein JN, Hunter L. EDGAR: extraction of drugs,
genes and relations from the biomedical literature. Pac Symp Biocomput
2000:517–28.
[16] Craven M, Kumlien J. Constructing biological knowledge bases by extracting
information from text sources. In: Proceedings of the seventh international
conference on intelligent systems for molecular biology. Heidelberg
(Germany): AAAI Press; 1999. p. 77–86.
[17] Roberts A, Gaizauskas R, Hepple M, Demetriou G, Guo Y, Setzer A. Semantic
annotation of clinical text: the CLEF corpus. In: Proceedings of the LREC 2008
workshop on building and evaluating resources for biomedical text mining;
2008. p. 19–26.
[18] Kim J-D, Ohta T, Tsujii J. Corpus annotation for mining biomedical events from
literature. BMC Bioinformatics 2008;9:10.
[19] Schuemie M, Jelier R, Kors JA. Peregrine: lightweight gene name normalization
by dictionary lookup. In: Proceedings of the Biocreative 2 workshop 2007,
April 23–25, Madrid; 2007. p. 131–40.
[20] http://bioie.ldc.upenn.edu/wiki/index.php/Main_Page.
[21] http://www.knewco.com.
